More Evidence Backing Anti-CDK4/6-Based Therapy in Recurrent Endometrial Cancer

(MedPage Today) -- Almost a third of patients with recurrent estrogen receptor (ER)-positive endometrial cancer responded to the combination of letrozole and abemaciclib (Verzenio) in a small phase II study.
Nine of 30 patients responded to the...